Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

被引:5
作者
Ji, Ying [1 ]
Wang, Yan-Li [2 ]
Xu, Fang [1 ]
Jia, Xi-Bei [1 ]
Mu, Su-Hong [1 ]
Lyu, Hui-Yan [1 ]
Yuan, Xue-Ying [1 ]
Na, Shi-Ping [1 ]
Bao, Yu-Shi [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Nephrol, 23 Youzheng St, Harbin 150001, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Rheumatol, Harbin, Peoples R China
关键词
podoplanin; C-type lectin-like receptor 2; nephrotic syndrome; hypercoagulable state; thrombosis; VENOUS THROMBOSIS; TUMOR-METASTASIS; RECEPTOR CLEC-2; THROMBOEMBOLISM; PLATELETS; INTEGRITY; ROLES; MICE;
D O I
10.1177/10760296221108967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = -0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome
    Trachtman, Howard
    Laskowski, Jennifer
    Lee, Cameron
    Renner, Brandon
    Feemster, Andrew
    Parikh, Samir
    Panzer, Sarah E.
    Zhong, Weixiong
    Cravedi, Paolo
    Cantarelli, Chiara
    Kulik, Liudmila
    You, Zhiying
    Satchell, Simon
    Rovin, Brad
    Liu, Fei
    Kalled, Susan L.
    Holers, V. Michael
    Jalal, Diana
    Thurman, Joshua M.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2021, 321 (04) : F505 - F516
  • [32] Ocular complications of paediatric patients with nephrotic syndrome
    Ng, JSK
    Wong, W
    Law, RWK
    Hui, J
    Wong, EN
    Lam, DSC
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2001, 29 (04) : 239 - 243
  • [33] Venous thromboembolism in patients hospitalized with nephrotic syndrome
    Kayali, Fadi
    Najjar, Reiad
    Aswad, Firas
    Matta, Fadi
    Stein, Paul D.
    AMERICAN JOURNAL OF MEDICINE, 2008, 121 (03) : 226 - 230
  • [34] Risk and Prognosis of Cancer in Patients with Nephrotic Syndrome
    Christiansen, Christian F.
    Onega, Tracy
    Svaerke, Claus
    Farkas, Dora Kormendine
    Jespersen, Bente
    Baron, John A.
    Sorensen, Henrik Toft
    AMERICAN JOURNAL OF MEDICINE, 2014, 127 (09) : 871 - +
  • [35] Increased arterial stiffness in patients with nephrotic syndrome
    Gungor, Ozkan
    Demirci, Meltem Sezis
    Kircelli, Fatih
    Tatar, Erhan
    Sipahi, Savas
    Hur, Ender
    Sen, Sait
    Toz, Huseyin
    Basci, Ali
    Ok, Ercan
    CLINICAL NEPHROLOGY, 2013, 79 (01) : 1 - 6
  • [36] Thyroid function in patients with idiopathic nephrotic syndrome
    Singh, Shivendra
    Mishra, Om Prakash
    Mandal, Partha Pratim
    Patel, Prem Shankar
    Sharma, Shiv Shankar
    Saini, Harish
    Rani, Khushboo
    Chandrasekhar, Sreenidhi
    Singh, Manjit Pal
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (09) : 1859 - 1864
  • [37] Dicer and Drosha expression in patients with nephrotic syndrome
    Hejazian, Seyyedeh Mina
    Rahbar Saadat, Yalda
    Bahmanpour, Zahra
    Hosseiniyan Khatibi, Seyed Mahdi
    Ardalan, Mohammadreza
    Zununi Vahed, Sepideh
    BIOFACTORS, 2020, 46 (04) : 645 - 652
  • [38] Study of urinary proteomes in patients with nephrotic syndrome
    Vojtova, L.
    Zima, T.
    Tesar, V.
    Kazderova, M.
    FOLIA BIOLOGICA, 2007, 53 (02) : 58 - 65
  • [39] Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome
    Ishikura, Kenji
    Ikeda, Masahiro
    Hamasaki, Yuko
    Hataya, Hiroshi
    Nishimura, Gen
    Hiramoto, Ryugo
    Honda, Masataka
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (08) : 2531 - 2536
  • [40] Thyroid function in patients with idiopathic nephrotic syndrome
    Shivendra Singh
    Om Prakash Mishra
    Partha Pratim Mandal
    Prem Shankar Patel
    Shiv Shankar Sharma
    Harish Saini
    Khushboo Rani
    Sreenidhi Chandrasekhar
    Manjit Pal Singh
    International Urology and Nephrology, 2021, 53 : 1859 - 1864